TAZIDIME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAZIDIME (TAZIDIME).
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
| Metabolism | Ceftazidime is not significantly metabolized; it is primarily excreted unchanged in the urine via glomerular filtration. |
| Excretion | Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%. |
| Half-life | 1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD). |
| Protein binding | Approximately 17% (primarily albumin). |
| Volume of Distribution | 0.21-0.30 L/kg; indicates distribution primarily in extracellular fluid. |
| Bioavailability | IM: 100% (fully absorbed). |
| Onset of Action | IV: Immediate (peak serum concentration at end of infusion); IM: 30-60 minutes. |
| Duration of Action | 6-8 hours in normal renal function; extended to 24 hours or more in severe renal impairment. |
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 31-50 mL/min: 1 g q12h; CrCl 16-30 mL/min: 1 g q24h; CrCl 6-15 mL/min: 500 mg q24h; CrCl <5 mL/min: 500 mg q48h. |
| Liver impairment | No adjustment required for hepatic impairment; dose based on renal function. |
| Pediatric use | Neonates (0-4 weeks): 30 mg/kg IV q12h (≤7 days) or q8h (>7 days); Infants/children (1 month-12 years): 30-50 mg/kg IV/IM q8h (max 6 g/day). |
| Geriatric use | Initiate with lower dose range; adjust based on renal function per creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAZIDIME (TAZIDIME).
| Breastfeeding | Ceftazidime excreted in breast milk in small amounts (M/P ratio ~0.08). Considered compatible with breastfeeding by the American Academy of Pediatrics, but monitor infant for diarrhea, candidiasis, and allergic reactions. |
| Teratogenic Risk | Teratogenic effects not observed in animal studies; inadequate human data. Renal effects (oligohydramnios) possible if used in late pregnancy. Risk Category B (FDA). Caution in second and third trimester due to potential fetal renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ceftazidime or any component of the formulation","Hypersensitivity to other cephalosporins or beta-lactam antibiotics"]
| Precautions | ["Hypersensitivity reactions, including anaphylaxis, may occur","Clostridioides difficile-associated diarrhea (CDAD) reported","Neurologic toxicity (seizures, encephalopathy) especially in patients with renal impairment","Development of drug-resistant bacteria","Hemolytic anemia (positive Coombs test)","Renal function impairment requires dose adjustment","Potentially prothrombin activity reduction and bleeding risk (rare)"] |
Loading safety data…
| Monitor maternal renal function (serum creatinine, BUN) and fluid/electrolyte balance. Assess fetal well-being if prolonged therapy in pregnancy; ultrasound for amniotic fluid volume if risk of oligohydramnios. Watch for signs of Clostridioides difficile infection. |
| Fertility Effects | No adverse effects on fertility reported in animal studies. No human data available regarding impact on male or female fertility. |